Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
2(25%)
Results Posted
167%(5 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
3
38%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(3)
Terminated(3)

Detailed Status

Completed3
Terminated3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (62.5%)
Phase 23 (37.5%)

Trials by Status

completed338%
recruiting225%
terminated338%

Recent Activity

2 active trials
Showing 5 of 8
terminatedphase_2

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

NCT03856216
recruitingphase_2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT00801489
recruitingphase_1

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

NCT04022239
terminatedphase_1

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT05032183
completedphase_1

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

NCT03417284
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03856216Phase 2

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Terminated
NCT00801489Phase 2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting
NCT04022239Phase 1

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting
NCT05032183Phase 1

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated
NCT03417284Phase 1

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Completed
NCT03096782Phase 2

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Completed
NCT01946152Phase 1

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated
NCT01787474Phase 1

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8